{
    "analyze": {
        "Part 1": {
            "Title": "Sample Collection and Preparation",
            "Referability": "High",
            "Reason": "The steps outlined in this part are directly applicable to the collection and preparation of RNA-seq data from sarcoma samples, which aligns with the objectives of our research.",
            "Suggestions": "We can use the same datasets (TCGA and GTEx) and follow similar steps for data download and preprocessing. However, we should ensure that the specific sarcoma subtypes relevant to our study (highly differentiated and dedifferentiated liposarcoma) are prioritized. Additionally, we might need to adjust the sample selection criteria to focus on these subtypes. Allocate part of the funding to ensure high-quality sample preparation and sequencing. Clearly document the sample selection criteria and preprocessing steps to ensure reproducibility."
        },
        "Part 2": {
            "Title": "Estimation of Signal Transduction Circuit Activity",
            "Referability": "Medium",
            "Reason": "While the mechanistic modeling of signal transduction using HiPathia is relevant, our primary focus is on metabolic characteristics. However, understanding signaling pathways could provide insights into metabolic regulation.",
            "Suggestions": "We can adopt the HiPathia tool for signal transduction analysis to complement our metabolic study. This might involve additional steps to integrate signaling and metabolic pathways. We should also consider using tools specifically designed for metabolic pathway analysis. Ensure the integration of signaling and metabolic pathway data is well-documented and justified. Provide a rationale for the selection of HiPathia and explain how it complements our focus on metabolic characteristics."
        },
        "Part 3": {
            "Title": "Survival Analysis of Sarcoma Patients",
            "Referability": "Low",
            "Reason": "Survival analysis is not directly related to our primary objective of comparing metabolic characteristics. However, it could provide additional context if we decide to explore prognostic factors.",
            "Suggestions": "If we choose to incorporate survival analysis, we can follow the steps outlined here. We should focus on the survival impact of metabolic gene expression and pathway activity. This would require integrating clinical data with our RNA-seq and single-cell sequencing data. Allocate resources to obtain and preprocess clinical data. Clearly document the steps for integrating clinical data with gene expression data."
        },
        "Part 4": {
            "Title": "Analysis of Transcription Factor Activation",
            "Referability": "Medium",
            "Reason": "Transcription factor activation analysis can provide insights into the regulatory mechanisms driving metabolic differences. This could be relevant to understanding the underlying biology of liposarcoma differentiation.",
            "Suggestions": "We can use the TFTEA tool to analyze transcription factor activity related to metabolic pathways. This would involve identifying key transcription factors that regulate metabolic genes and pathways in highly differentiated vs. dedifferentiated liposarcoma. Ensure that the focus remains on transcription factors relevant to metabolic regulation. Provide a detailed rationale for the selection of TFTEA and explain how it contributes to understanding metabolic regulation."
        },
        "Part 5": {
            "Title": "Differential Signaling Analysis",
            "Referability": "High",
            "Reason": "Differential signaling analysis is highly relevant as it can help identify key pathways and circuits that differ between highly differentiated and dedifferentiated liposarcoma.",
            "Suggestions": "We should adapt the differential signaling analysis to focus on metabolic pathways. This involves using the limma package for differential expression analysis and performing functional annotation specific to metabolic processes. Ensure that the analysis is well-documented and justifies the selection of metabolic pathways. Provide a detailed explanation of the limma package and its relevance to our study."
        },
        "Part 6": {
            "Title": "Association with Hallmarks of Cancer",
            "Referability": "Medium",
            "Reason": "Associating differentially activated circuits with cancer hallmarks can provide a broader understanding of the biological significance of our findings. This can be useful for contextualizing metabolic differences within the framework of cancer biology.",
            "Suggestions": "We should use the CHAT tool to annotate our findings with cancer hallmarks, emphasizing those related to metabolism. This will help in understanding how metabolic characteristics contribute to cancer progression and differentiation in liposarcoma. Ensure that the focus remains on hallmarks relevant to metabolic processes. Provide a detailed explanation of the CHAT tool and its relevance to our study."
        },
        "Referability": 0.3333333333333333
    },
    "history": [
        {
            "role": "user",
            "content": [
                {
                    "type": "text",
                    "text": "You are a researcher. In order to carry out your research, you first carried out a literature search, the following is an experimental protocol organized from a relevant piece of literature you obtained from your search. Read each part of the experimental protocol carefully and analyze whether you can refer to that section in your research in the context of the purpose and conditions of your research, giving a referability rating (low, medium, or high) for each part and explaining why; and giving suggestions for references (eg. what methods you can learn from it and what datasets mentioned in the protocol can be used for your research) and modifications (eg. what should be changed for fit your research) to fit your research. \n\nProtocol:RNA-seq based analysis reveals differences in metabolic characteristics between highly differentiated and dedifferentiated liposarcoma.\n\nHere is your research objective:Available Resources: Frozen samples, sarcoma cell lines, and paraffin sections. Data Sources: RNA sequencing data from 80 cases and single-cell sequencing data from 10 cases, along with any publicly available datasets. Animal Experiments: All necessary materials are available if required. Funding: The total funding for the experiment is 200,000 RMB. Computing Resources: Sufficient computing resources are accessible for data analysis.. \nYour research conditions are as follows:null. \nThe mandatory requirements you must fulfill in your experimental design are listed below: <article-title>Functional Profiling of Soft Tissue Sarcoma Using Mechanistic Models</article-title>\n      : \n\n{\n    \"Part 1\": \"Sample Collection and Preparation\",\n    \"step 1\": {\n        \"implementation details\": \"I. Data Download from Recount3:\\n(1) Download raw gene counts for tumor and normal tissue samples from the Recount3 R package (version 1.0).\\n(2) Ensure the raw reads from multiple sources, including cancer and non-diseased tissues generated by the TCGA and the Genotype-Tissue Expression Project (GTEx), were uniformly processed with a pipeline using STAR (version 2.7.3a) and Megadepth (version 1.0.1) to align and quantify the reads to the UCSC hg38 assembly.\\n(3) Access and download the raw gene counts using specific commands or code snippets provided in the Recount3 documentation. For example:\\nR\\nlibrary(recount3)\\nproject_info <- available_projects()\\n# Download data for TCGA SARC project\\ndata_sarc <- create_rse(project = 'TCGA-SARC')\\n# Download data for GTEx project\\ndata_gtex <- create_rse(project = 'GTEx')\\n\\n\",\n        \"original text\": \"Raw gene counts for tumor and normal tissue samples were obtained from the recount3 R package [33]. Recount3 provides RNA-Seq dataset counts where raw reads from multiple sources, including cancer and non-diseased tissues generated by the TCGA and the Genotype-Tissue Expression Project (GTEx), respectively, were uniformly processed with a pipeline using STAR [34] and Megadepth [35] to align and quantify the reads to the UCSC hg38 assembly.\",\n        \"results\": \"Selected data from GTEx tissues and the SARC project were downloaded. Samples from GTEx on putative sarcomagenic tissues of mesenchymal origin were: 1293 adipose, 520 fibroblasts, 881 skeletal muscle, 553 esophagus muscularis, 384 stomach, 159 uterus, and 946 vessels. From TCGA, the 206 sarcoma samples include 7 subtypes: 50 dedifferentiated liposarcomas (DDLPS), 80 leiomyosarcomas (divided into 53 soft tissue STLMS and 27 uterine ULMS), 5 malignant peripheral nerve sheath tumors (MPNST), 17 myxofibrosarcomas (MFS), 10 synovial sarcomas (SS), and 44 undifferentiated pleomorphic sarcoma (UPS).\",\n        \"results original text\": \"Selected data from GTEx tissues and the SARC project were downloaded. Samples from GTEx on putative sarcomagenic tissues of mesenchymal origin were: 1293 adipose, 520 fibroblasts, 881 skeletal muscle, 553 esophagus muscularis, 384 stomach, 159 uterus, and 946 vessels. From TCGA, the 206 sarcoma samples include 7 subtypes: 50 dedifferentiated liposarcomas (DDLPS), 80 leiomyosarcomas (divided into 53 soft tissue STLMS and 27 uterine ULMS), 5 malignant peripheral nerve sheath tumors (MPNST), 17 myxofibrosarcomas (MFS), 10 synovial sarcomas (SS), and 44 undifferentiated pleomorphic sarcoma (UPS).\"\n    },\n    \"step 2\": {\n        \"implementation details\": \"II. Selection Criteria for Sarcoma and Normal Tissue Samples:\\n(1) Tumor samples were obtained from the SARC project, belonging to the TCGA consortium.\\n(2) Normal samples were downloaded from multiple tissue projects of the GTEx consortium and further selected for specific tissue site details (e.g., adipose, uterus, esophagus, stomach, blood vessel, muscle, and skin fibroblasts).\\n(3) Filter out low-quality and non-primary tumor samples from the sarcoma project based on read alignment statistics (e.g., percentage of aligned reads > 70%) and visual inspection of data distribution.\\n(4) The subtype classification was modified according to previous expert pathology reviews, as detailed in the supplementary information of the referenced study.\",\n        \"original text\": \"Tumor samples were obtained from the SARC project, belonging to the TCGA consortium, while normal samples were downloaded from multiple tissue projects of the GTEx consortium [36] and further selected for specific tissue site details (Table 4). Low-quality and non-primary tumor samples from the sarcoma project were filtered out. The subtype classification was modified according to previous expert pathology reviews [37].\",\n        \"results\": \"Data exploration by dimensionality reduction with t-SNE and clustering showed a strong correlation of samples by the project. On sarcoma, most LMS samples, divided by uterine or soft tissue LMS and SS samples, formed close clusters.\",\n        \"results original text\": \"Data exploration by dimensionality reduction with t-SNE and clustering showed a strong correlation of samples by the project (Figure S1). On sarcoma, most LMS samples, divided by uterine or soft tissue LMS and SS samples, formed close clusters.\"\n    },\n    \"step 3\": {\n        \"implementation details\": \"III. Preprocessing of Raw Gene Counts:\\n(1) Mapping Genomic Features: Keep genomic features mapped to an Entrez ID on the org.Hs.eg.db Bioconductor package (version 3.12.0).\\n(2) Normalization Process: Normalize the downloaded raw counts for all samples using the Trimmed Mean of M-values (TMM) method, as implemented in the edgeR package (version 3.32.1), which computes scaling factors assuming that most genes are not differentially expressed.\\n(3) Obtain normalized counts in the log scale with the voom function provided in the limma package (version 3.46.0), which also models the mean\\u2013variance relationship of normalized values with precision weights suitable for the analysis of differential gene expression.\\n(4) Quality Control Checks: Perform quality control checks on the raw gene counts, including visualizing the data distribution, checking for outliers, and ensuring data integrity using specific R packages for data quality assessment (e.g., edgeR, limma).\",\n        \"original text\": \"We kept genomic features mapped to an Entrez ID on the org.Hs.eg.db Bioconductor package v3.12.0 [38]. The downloaded raw counts for all samples were normalized using the Trimmed Mean of M-values (TMM) method [39], as implemented in the edgeR package [40] version 3.32.1, which computes scaling factors assuming that most genes are not differentially expressed. Normalized counts in the log scale were obtained with the voom function provided in the limma package version 3.46.0 [41], which also models the mean\\u2013variance relationship of normalized values with precision weights suitable for the analysis of differential gene expression.\",\n        \"results\": \"Downloaded gene read counts from these samples were preprocessed together with TMM normalization and used for the estimation of activity values with HiPathia.\",\n        \"results original text\": \"Downloaded gene read counts from these samples were preprocessed together with TMM normalization and used for the estimation of activity values with HiPathia.\"\n    },\n    \"step 4\": {\n        \"implementation details\": \"IV. Normalization of Gene Counts using TMM method:\\n(1) Normalize raw gene counts using the TMM method to account for differences in library sizes and composition.\\n(2) Apply the voom function to transform the normalized counts to log2 counts per million (CPM) and estimate the mean-variance relationship.\\n(3) Justify the choice of normalization methods, explaining how the TMM method and voom function address potential biases and ensure accurate downstream analysis. For example, the TMM method accounts for differences in library sizes and composition, while the voom function models the mean-variance relationship to provide precision weights for differential expression analysis.\\n(4) Consider alternative normalization methods (e.g., DESeq2) and provide a rationale for selecting the TMM and voom approaches.\",\n        \"original text\": \"The downloaded raw counts for all samples were normalized using the Trimmed Mean of M-values (TMM) method [39], as implemented in the edgeR package [40] version 3.32.1, which computes scaling factors assuming that most genes are not differentially expressed. Normalized counts in the log scale were obtained with the voom function provided in the limma package version 3.46.0 [41], which also models the mean-variance relationship of normalized values with precision weights suitable for the analysis of differential gene expression.\",\n        \"results\": \"Exploration of sample clustering with either t-SNE or a heatmap did not reveal significant differences compared to sample distances using expression values, indicating that this method preserves the biological information of samples.\",\n        \"results original text\": \"Exploration of sample clustering with either t-SNE or a heatmap did not reveal significant differences compared to sample distances using expression values (see Figure 1), indicating that this method preserves the biological information of samples.\"\n    }\n}{\n    \"Part 2\": \"Estimation of Signal Transduction Circuit Activity\",\n    \"step 1\": {\n        \"implementation details\": \"I. Mechanistic Modeling of Human Signal Transduction using HiPathia\\n\\nOverview: This section describes the process of modeling human signal transduction using the HiPathia tool, which includes data collection, preprocessing, and defining signaling circuits.\\n\\n\\u2460 Data Collection and Preprocessing:\\n(1) Download raw gene counts for tumor and normal tissue samples from the recount3 R package.\\n(2) Filter out low-quality and non-primary tumor samples from the sarcoma project.\\n(3) Normalize the downloaded raw counts using the Trimmed Mean of M-values (TMM) method as implemented in the edgeR package version 3.32.1.\\n(4) Obtain normalized counts in the log scale using the voom function provided in the limma package version 3.46.0.\\n(5) Parameters for STAR alignment: --runThreadN 8 --genomeDir /path/to/genome --readFilesIn /path/to/reads --outFileNamePrefix /path/to/output\\n(6) Parameters for Megadepth quantification: megadepth --annotation /path/to/annotation.gtf --out /path/to/output.bw /path/to/reads.bam\\n(7) Handle missing data or low-quality reads by removing reads with low mapping quality (MAPQ < 20) using `samtools view -q 20 input.bam > filtered.bam` and filtering out genes with low expression levels (e.g., counts per million < 1 in at least 50% of samples) using the `filterByExpr` function in edgeR.\\n\\n\\u2461 Signal Transduction Circuit Definition:\\n(1) Select 78 physiological signaling pathways from the KEGG database.\\n(2) Define individual signaling circuits within the pathways using HiPathia.\\n(3) Each circuit is composed of nodes connected by activating or inhibiting relationships, ending in a single effector node responsible for specific cellular functions.\",\n        \"original text\": \"Raw gene counts for tumor and normal tissue samples were obtained from the recount3 R package [33]. Recount3 provides RNA-Seq dataset counts where raw reads from multiple sources, including cancer and non-diseased tissues generated by the TCGA and the Genotype-Tissue Expression Project (GTEx), respectively, were uniformly processed with a pipeline using STAR [34] and Megadepth [35] to align and quantify the reads to the UCSC hg38 assembly. Tumor samples were obtained from the SARC project, belonging to the TCGA consortium, while normal samples were downloaded from multiple tissue projects of the GTEx consortium [36] and further selected for specific tissue site details (Table 4).\\n\\nThe downloaded raw counts for all samples were normalized using the Trimmed Mean of M-values (TMM) method [39], as implemented in the edgeR package [40] version 3.32.1, which computes scaling factors assuming that most genes are not differentially expressed. Normalized counts in the log scale were obtained with the voom function provided in the limma package version 3.46.0 [41], which also models the mean\\u2013variance relationship of normalized values with precision weights suitable for the analysis of differential gene expression.\\n\\nHiPathia (HIgh throughput PATHway Interpretation and Analysis) is designed to transform gene count data into the activity of signaling pathways divided into single-effector circuits that drive specific cell functions [13,26]. Human physiological pathways were provided to the hipathia function. The function normalize_paths was used to account for the length of the circuits in the activity calculation.\",\n        \"results\": \"Exploration of sample clustering with either t-SNE or a heatmap did not reveal significant differences compared to sample distances using expression values (see Figure 1), indicating that this method preserves the biological information of samples.\",\n        \"results original text\": \"Exploration of sample clustering with either t-SNE or a heatmap did not reveal significant differences compared to sample distances using expression values (see Figure 1), indicating that this method preserves the biological information of samples.\"\n    },\n    \"step 2\": {\n        \"implementation details\": \"II. Calculation of Pathway Activity\\n\\nOverview: This section explains how to calculate the activity of signaling pathways using the HiPathia tool.\\n\\n\\u2460 Rescaling Normalized Values:\\n(1) Rescale normalized values to the range 0\\u20131 using the function normalize_data from the HiPathia package.\\n\\n\\u2461 Pathway Activity Calculation:\\n(1) Use the hipathia function to transform gene count data into the activity of signaling pathways divided into single-effector circuits.\\n(2) Normalize the pathway activity calculation to account for the length of the circuits using the normalize_paths function.\\n(3) Example command for HiPathia analysis: hipathia_results <- hipathia(data = normalized_data, pathways = human_pathways, normalize_paths = TRUE)\\n(4) Troubleshooting tips: If the HiPathia function returns an error, check for missing values in the input data and ensure all required dependencies are installed.\",\n        \"original text\": \"Prior to pathway activity computation, normalized values were rescaled to the range 0\\u20131 using the function normalize_data from the package HiPathia 2.6.0 [46]. HiPathia (HIgh throughput PATHway Interpretation and Analysis) is designed to transform gene count data into the activity of signaling pathways divided into single-effector circuits that drive specific cell functions [13,26]. Human physiological pathways were provided to the hipathia function. The function normalize_paths was used to account for the length of the circuits in the activity calculation.\",\n        \"results\": \"A total of 1098 signaling circuits were identified by HiPathia within the 78 physiological KEGG pathways.\",\n        \"results original text\": \"HiPathia defines individual signaling circuits within the pathways to individualize functional activities. Each circuit is composed of nodes connected by activating or inhibiting relationships and ends in a single effector node, which is responsible for the cellular functions triggered by the circuit. A number of these functions can be ascribed to cancer hallmarks [29] with the CHAT tool [30,31], as described in the Methods section. A total of 1098 signaling circuits were identified by HiPathia within the 78 physiological KEGG pathways.\"\n    },\n    \"step 3\": {\n        \"implementation details\": \"III. Validation of Mechanistic Models\\n\\nOverview: This section describes how to validate the mechanistic models using external data and survival analysis.\\n\\n\\u2460 Validation using External Data:\\n(1) Validate the mechanistic models using external datasets such as TCGA and GTEx.\\n(2) Compare the predicted activity values with known biological functions and clinical outcomes.\\n(3) Preprocessing steps for external datasets: Normalize the data using the same TMM method and voom function as described in step I.\\n\\n\\u2461 Validation using Survival Analysis:\\n(1) Perform survival analysis on sarcoma samples using the survival R package.\\n(2) Compute Cox proportional hazards regression models to estimate differences in patient survival associated with circuit activity values.\\n(3) Example command for Cox regression: cox_model <- coxph(Surv(days_to_death, vital_status) ~ circuit_activity, data = sarcoma_data)\\n(4) Step-by-step guide for survival analysis: a) Create a survival object using the Surv function, b) Fit a Cox model using the coxph function, c) Test the proportional hazards assumption using the cox.zph function.\",\n        \"original text\": \"The mechanistic model replicates the dynamics of the signaling circuits defined within pathways. These circuits are depicted as directed graphs, establishing connections from receptor to effector proteins through a series of activations and inhibitions mediated by intermediate proteins. Ultimately, effector proteins at the end of these circuits initiate distinct cellular functions. Malfunctions of these circuits can trigger cancer hallmarks in neoplastic cells. The mechanistic model emulates signal transduction along these circuits by considering protein activity levels. In this context, gene expression values serve as proxies for the presence of their corresponding active proteins [42\\u201345]. Consequently, for a circuit to become active and effectively transmit the signal triggering a specific function, it necessitates the concurrent presence of the entire chain of proteins connecting the receptor to the effector while ensuring the absence of inhibitory proteins that might impede signal propagation along the circuit. Irrespective of the circuit\\u2019s topology, the signal propagates through the nodes within it based on the subsequent recursive rule for each node: Sn = \\u03c5n \\u00b7 (1 \\u2212\\u220f sa\\u2208A (1 \\u2212sa)) \\u00b7 \\u220f si\\u2208I (1 \\u2212si).\",\n        \"results\": \"Thirteen signaling circuits significantly associated with sarcoma patient survival were found. These circuits are part of pathways that are well-known drivers of tumorigenesis, such as NF-kB, RB1, or Akt, and other pathways related to the immune system.\",\n        \"results original text\": \"Thirteen signaling circuits significantly associated with sarcoma patient survival were found (Table 1 and Table S1). These circuits are part of pathways that are well-known drivers of tumorigenesis, such as NF-kB, RB1, or Akt, and other pathways related to the immune system.\"\n    },\n    \"step 4\": {\n        \"implementation details\": \"IV. Visualization of Normalized Counts and Activity Values\\n\\nOverview: This section details the methods for visualizing normalized counts and activity values using dimensionality reduction and heatmap visualization.\\n\\n\\u2460 Dimensionality Reduction:\\n(1) Use the t-distributed stochastic neighbor embedding (t-SNE) method for visualization of the structure of high-dimensional data.\\n(2) Utilize the Rtsne package for the t-SNE analysis.\\n(3) Parameters for t-SNE analysis: Rtsne(normalized_data, perplexity = 30, theta = 0.5, dims = 2)\\n\\n\\u2461 Heatmap Visualization:\\n(1) Create heatmaps using the pheatmap package with the complete clustering method.\\n(2) Use Euclidean distance for features and correlation for samples as distance measures.\\n(3) Example command for heatmap: pheatmap(normalized_data, clustering_distance_rows = 'euclidean', clustering_distance_cols = 'correlation')\\n(4) Troubleshooting tips: If the heatmap visualization is unclear, adjust the clustering method or distance measures and re-run the analysis.\",\n        \"original text\": \"Visualization of normalized counts and activity values was performed using the t-distributed stochastic neighbor embedding method (t-SNE) for visualization of the structure of high-dimensional data [47] using the function provided in the package Rtsne [48] version 0.15, as well as on heatmaps using the pheatmap package [49] version 1.0.12 with the complete clustering method and, as distance measures, euclidean for features and correlation for samples.\",\n        \"results\": \"Exploration of sample clustering with either t-SNE or a heatmap did not reveal significant differences compared to sample distances using expression values (see Figure 1), indicating that this method preserves the biological information of samples.\",\n        \"results original text\": \"Exploration of sample clustering with either t-SNE or a heatmap did not reveal significant differences compared to sample distances using expression values (see Figure 1), indicating that this method preserves the biological information of samples.\"\n    }\n}{\n    \"Part 3\": \"Survival Analysis of Sarcoma Patients\",\n    \"step 1\": {\n        \"implementation details\": \"I. Data Cleaning and Preparation for Survival Analysis\\n\\n**Objective:** Prepare raw gene count data for survival analysis by normalizing and filtering the data.\\n\\n**Steps:**\\n1. Download raw gene counts for tumor and normal tissue samples from the recount3 R package, specifically using the SARC project data for sarcoma samples and the GTEx project data for normal tissue samples.\\n2. Filter out low-quality and non-primary tumor samples from the sarcoma project.\\n3. Keep genomic features mapped to an Entrez ID on the org.Hs.eg.db Bioconductor package v3.12.0.\\n4. Normalize the downloaded raw counts for all samples using the Trimmed Mean of M-values (TMM) method implemented in the edgeR package version 3.32.1.\\n5. Obtain normalized counts in the log scale with the voom function provided in the limma package version 3.46.0, which models the mean-variance relationship of normalized values with precision weights suitable for the analysis of differential gene expression.\\n6. Handle missing values by imputing with the mean or median of the dataset, or by removing rows with excessive missing values.\\n\\n**Example R code:**\\nR\\nlibrary(recount3)\\nlibrary(edgeR)\\nlibrary(limma)\\n# Load data\\ndata <- recount3::download_study(\\\"SARC\\\")\\n# Filter low-quality samples\\ndata <- data[!data$sample_type %in% c(\\\"Solid Tissue Normal\\\", \\\"Recurrent Tumor\\\"), ]\\n# Normalize counts\\ndge <- DGEList(counts = data$counts)\\ndge <- calcNormFactors(dge, method = \\\"TMM\\\")\\nvoom_data <- voom(dge)\\n# Handle missing values\\nvoom_data <- na.omit(voom_data)\\n\\n\\n**Potential Pitfalls and Troubleshooting:**\\n- Ensure that the downloaded data is correctly aligned and quantified to avoid biases in the analysis.\\n- If normalization fails, check for outliers or extreme values in the raw counts and address them appropriately.\",\n        \"original text\": \"Raw gene counts for tumor and normal tissue samples were obtained from the recount3 R package. Recount3 provides RNA-Seq dataset counts where raw reads from multiple sources, including cancer and non-diseased tissues generated by the TCGA and the Genotype-Tissue Expression Project (GTEx), respectively, were uniformly processed with a pipeline using STAR and Megadepth to align and quantify the reads to the UCSC hg38 assembly. Tumor samples were obtained from the SARC project, belonging to the TCGA consortium, while normal samples were downloaded from multiple tissue projects of the GTEx consortium and further selected for specific tissue site details (Table 4). Low-quality and non-primary tumor samples from the sarcoma project were filtered out. The subtype classification was modified according to previous expert pathology reviews. We kept genomic features mapped to an Entrez ID on the org.Hs.eg.db Bioconductor package v3.12.0. The downloaded raw counts for all samples were normalized using the Trimmed Mean of M-values (TMM) method, as implemented in the edgeR package version 3.32.1, which computes scaling factors assuming that most genes are not differentially expressed. Normalized counts in the log scale were obtained with the voom function provided in the limma package version 3.46.0, which also models the mean\\u2013variance relationship of normalized values with precision weights suitable for the analysis of differential gene expression.\",\n        \"results\": \"Exploration of sample clustering with either t-SNE or a heatmap did not reveal significant differences compared to sample distances using expression values, indicating that this method preserves the biological information of samples.\",\n        \"results original text\": \"Exploration of sample clustering with either t-SNE or a heatmap did not reveal significant differences compared to sample distances using expression values (see Figure 1), indicating that this method preserves the biological information of samples.\"\n    },\n    \"step 2\": {\n        \"implementation details\": \"II. Creation of Censored Survival Object\\n\\n**Objective:** Create a censored survival object for survival analysis using clinical metadata.\\n\\n**Steps:**\\n1. Gather maximum values of 'days to death' or 'days to last follow-up,' with vital status as a censoring variable, from the clinical metadata of TCGA samples in Recount3.\\n2. Handle missing data by omitting rows with NA values or imputing with the mean or median of the dataset.\\n3. Create the censored survival object using the survival R package.\\n\\n**Example R code:**\\nR\\nlibrary(survival)\\n# Load clinical data\\nclinical_data <- recount3::download_study(\\\"SARC_clinical\\\")\\n# Handle missing data\\nclinical_data <- na.omit(clinical_data)\\n# Create survival object\\nsurv_obj <- Surv(time = clinical_data$days_to_event, event = clinical_data$event_status)\\n\\n\\n**Potential Pitfalls and Troubleshooting:**\\n- Ensure that the clinical metadata is correctly matched with the gene expression data to avoid discrepancies in the survival analysis.\\n- If there are many missing values, consider using multiple imputation methods to handle the missing data more robustly.\",\n        \"original text\": \"Survival analysis was performed on sarcoma samples using the survival R package version 3.2\\u201310. From this package, Cox proportional hazards regression models were computed to estimate differences in patient survival in association with circuit activity or gene expression values. To create the censored survival object, maximum values of 'days to death' or 'days to last follow-up,' with vital status as a censoring variable, were gathered from the clinical metadata of TCGA samples in Recount3.\",\n        \"results\": \"The censored survival object was successfully created using the maximum values of 'days to death' or 'days to last follow-up' with vital status as a censoring variable.\",\n        \"results original text\": \"To create the censored survival object, maximum values of 'days to death' or 'days to last follow-up,' with vital status as a censoring variable, were gathered from the clinical metadata of TCGA samples in Recount3.\"\n    },\n    \"step 3\": {\n        \"implementation details\": \"III. Cox Proportional Hazards Regression Models\\n\\n**Objective:** Estimate differences in patient survival in association with circuit activity or gene expression values using Cox proportional hazards regression models.\\n\\n**Steps:**\\n1. Compute a model for each circuit using the coxph function from the survival R package.\\n2. Adjust the p-value of each model for multiple tests with the Benjamini and Hochberg method (FDR, false discovery rate).\\n3. Test the proportional hazards assumption with the cox.zph function of the survival package.\\n4. If the coxph function returns an error due to convergence issues, try scaling the input data or using a different optimization method.\\n\\n**Example R code:**\\nR\\ncox_model <- coxph(surv_obj ~ gene_expression + age + gender, data = clinical_data)\\nsummary(cox_model)\\n# Test proportional hazards assumption\\nzph_test <- cox.zph(cox_model)\\nprint(zph_test)\\n\\n\\n**Potential Pitfalls and Troubleshooting:**\\n- Ensure that the proportional hazards assumption is met for each model. If not, consider using stratified Cox models or adding interaction terms to address violations of the assumption.\\n- Check for multicollinearity among covariates, which can affect the stability and interpretability of the model coefficients.\",\n        \"original text\": \"A model for each circuit was computed with the coxph function. The p-value of each model was adjusted for multiple tests with the Benjamini and Hochberg method (FDR, false discovery rate). In addition to Cox regression, the proportional assumption was tested with the cox.zph function of the survival package.\",\n        \"results\": \"Thirteen signaling circuits significantly associated with sarcoma patient survival were found. These circuits are part of pathways that are well-known drivers of tumorigenesis, such as NF-kB, RB1, or Akt, and other pathways related to the immune system.\",\n        \"results original text\": \"Thirteen signaling circuits significantly associated with sarcoma patient survival were found (Table 1 and Table S1). These circuits are part of pathways that are well-known drivers of tumorigenesis, such as NF-kB, RB1, or Akt, and other pathways related to the immune system.\"\n    },\n    \"step 4\": {\n        \"implementation details\": \"IV. Kaplan\\u2013Meier Survival Curves\\n\\n**Objective:** Visualize the association of circuit activity levels with patient survival using Kaplan\\u2013Meier survival curves.\\n\\n**Steps:**\\n1. Construct Kaplan\\u2013Meier survival curves with the Survminer package version 0.4.9 from selected patients with high and low circuit activity.\\n2. Define high and low circuit activity levels based on scaling activity levels into z-scores and setting a cutoff of +/-0.5, corresponding to the 25% upper and lower percentile of the observed values, respectively.\\n\\n**Example R code:**\\nR\\nlibrary(survminer)\\n# Define high and low activity groups\\nclinical_data$activity_group <- ifelse(clinical_data$gene_expression > 0.5, 'High', 'Low')\\n# Plot Kaplan-Meier curves\\nggsurvplot(survfit(surv_obj ~ activity_group, data = clinical_data), \\n           pval = TRUE, conf.int = TRUE, \\n           risk.table = TRUE, \\n           ggtheme = theme_minimal())\\n\\n\\n**Potential Pitfalls and Troubleshooting:**\\n- Ensure that the cutoffs for high and low activity groups are appropriately chosen to reflect meaningful differences in survival curves.\\n- If the survival curves cross, consider using alternative methods such as time-dependent Cox models to account for non-proportional hazards.\",\n        \"original text\": \"Kaplan\\u2013Meier survival curves were constructed with the Survminer package version 0.4.9 from selected patients with high and low circuit activity. High and low circuit activity level was defined based on scaling activity levels into z-scores and setting a cutoff of +/-0.5, corresponding to the 25% upper and lower percentile of the observed values, respectively.\",\n        \"results\": \"Kaplan\\u2013Meier survival curves were plotted for the 13 significant circuits, showing the association of high and low circuit activity levels with patient survival.\",\n        \"results original text\": \"Kaplan\\u2013Meier survival curves were constructed with the Survminer package version 0.4.9 from selected patients with high and low circuit activity.\"\n    }\n}{\n    \"Part 4\": \"Analysis of Transcription Factor Activation\",\n    \"step 1\": {\n        \"implementation details\": \"I. Introduction/Overview:\\nThis section focuses on analyzing transcription factor activation using the TFTEA tool. The objective is to understand the regulatory mechanisms underlying the observed gene expression changes in sarcoma samples. The steps include indirect estimation of transcription factor activity, enrichment analysis, functional annotation, and validation of predictions. This part of the protocol contributes to the study by identifying key transcription factors that may drive the observed changes in gene expression, ultimately affecting sarcoma progression and patient outcomes.\",\n        \"original text\": \"\",\n        \"results\": \"The analysis revealed that several transcription factors have their targets significantly overrepresented in the differentially expressed genes. Notably, SPI1 (a.k.a. PU.1) and IKZF1 (Ikaros protein) were found to have a significant number of targets within the signaling circuits whose expression is dysregulated.\",\n        \"results original text\": \"The results indicate that the most shared transcription factors by sarcoma subtypes have target genes overrepresented in the overexpressed part of the rank (Table 2 and Table S2). SPI1 (a.k.a. PU.1) is the TF whose targets are present in most of the circuits. In particular, it has 41 targets within the signaling circuits whose expression is dysregulated, including PIK3CG and AKT2, central components of the PI3K/Akt signaling network present in various pathways, as well as components of the MAPK signaling network such as IKBKB, MAPK10, or RAC2. IKZF1 (Ikaros protein) targets participate in the protective circuits of the Fc epsilon signaling pathway, platelet activation, and HIF-1 signaling pathway. Among Ikaros targets, Lyn kinase and PRKCB (protein kinase C, beta subunit) were found to be upregulated. Lyn participates in the activation of PI3K/Akt networks within the indicated pathways, while it activates PKC by downstream calcium signaling.\"\n    },\n    \"step 2\": {\n        \"implementation details\": \"II. Data Quality Control:\\n1. Check for outliers in the gene expression data using statistical methods such as boxplots and principal component analysis (PCA).\\n2. Ensure that the data meets quality criteria such as minimum read counts (e.g., >10 counts per million in at least 50% of the samples) and absence of technical artifacts using tools like FastQC and MultiQC.\\n3. Use the edgeR and limma packages for normalization and variance modeling. Ensure that normalization is done using the TMM method and variance modeling using the voom function.\",\n        \"original text\": \"\",\n        \"results\": \"The gene expression data was preprocessed together with TMM normalization and used for the estimation of activity values with HiPathia. Data exploration by dimensionality reduction with t-SNE and clustering showed a strong correlation of samples by the project.\",\n        \"results original text\": \"Downloaded gene read counts from these samples were preprocessed together with TMM normalization and used for the estimation of activity values with HiPathia. Data exploration by dimensionality reduction with t-SNE and clustering showed a strong correlation of samples by the project (Figure S1). On sarcoma, most LMS samples, divided by uterine or soft tissue LMS and SS samples, formed close clusters.\"\n    },\n    \"step 3\": {\n        \"implementation details\": \"III. Indirect Estimation of Transcription Factor Activity using TFTEA:\\n1. Use the Transcription Factor Target Enrichment Analysis (TFTEA) tool to assess the activity of transcription factors (TFs) indirectly by analyzing the activity of their target genes.\\n2. Obtain the set of transcription factor\\u2013target interactions from the Dorothea database, selecting interactions with support from at least two sources (confidence levels A, B, and C).\\n3. Ensure that the differential expression analysis results are ranked and saved in a file named 'DEGs.txt' for input into TFTEA.\\n4. Use the following command to perform the analysis: `TFTEA --input DEGs.txt --output TF_enrichment.txt --model logistic --confidence_levels A,B,C`.\\n5. Interpret the results to identify transcription factors with significant activity changes.\",\n        \"original text\": \"The results of differential expression analysis were used for indirect estimation of transcription factor activity by enrichment analysis of their corresponding target genes using the Transcription Factor Target Enrichment Analysis (TFTEA) [27] tool. TFTEA carries out an enrichment analysis of targets for each transcription factor over a list of ranked DEGs using univariate gene set analysis with a logistic regression model. The set of transcription factor\\u2013target interactions used in this analysis was obtained from the papers describing TFTEA [27] and Dorothea, a database that collects transcription factors\\u2019 targets (regulons) [56]. From the Dorothea database, transcription factor\\u2013target interactions with support from at least two sources (confidence levels A, B, and C, as defined in [56]) were selected.\",\n        \"results\": \"A total of 130 TF targets along the circuits associated with survival were found, 65 of which were dysregulated.\",\n        \"results original text\": \"A total of 130 TF targets along the circuits associated with survival were found, 65 of which were dysregulated.\"\n    },\n    \"step 4\": {\n        \"implementation details\": \"IV. Enrichment Analysis of Transcription Factor Targets:\\n1. Perform enrichment analysis of transcription factor targets using the logistic regression model implemented in TFTEA. Use the following command:\\n`TFTEA --input DEGs.txt --output TF_enrichment.txt --model logistic --confidence_levels A,B,C`\\n2. Rank the differentially expressed genes (DEGs) and assess the enrichment of transcription factor targets within this ranked list.\\n3. Interpret the enrichment results to identify transcription factors with significant activity changes. Provide example outputs or expected results to guide users.\",\n        \"original text\": \"TFTEA carries out an enrichment analysis of targets for each transcription factor over a list of ranked DEGs using univariate gene set analysis with a logistic regression model.\",\n        \"results\": \"The results indicate that the most shared transcription factors by sarcoma subtypes have target genes overrepresented in the overexpressed part of the rank.\",\n        \"results original text\": \"The results indicate that the most shared transcription factors by sarcoma subtypes have target genes overrepresented in the overexpressed part of the rank (Table 2 and Table S2).\"\n    },\n    \"step 5\": {\n        \"implementation details\": \"V. Functional Annotations of Genes using COSMIC, ONGENE, TSGENE databases:\\n1. Gather functional annotations of genes from the COSMIC Cancer Gene Census v96, ONGENE, and TSGENE databases.\\n2. Annotate the transcription factors and their targets with information about their roles in cancer from these databases.\\n3. Use the functional annotations to provide context for the observed transcription factor activity changes and their potential impact on sarcoma biology. Provide specific examples of how the annotations are used to interpret results.\",\n        \"original text\": \"Functional annotations of genes were gathered from the COSMIC Cancer Gene Census v96 [57] and the databases ONGENE [58] and TSGENE [59].\",\n        \"results\": \"SPI1 (a.k.a. PU.1) and IKZF1 (Ikaros protein) were found to have significant roles in the regulatory mechanisms underlying sarcoma progression. SPI1 has 41 targets within the signaling circuits whose expression is dysregulated, including PIK3CG and AKT2, central components of the PI3K/Akt signaling network.\",\n        \"results original text\": \"SPI1 (a.k.a. PU.1) is the TF whose targets are present in most of the circuits. In particular, it has 41 targets within the signaling circuits whose expression is dysregulated, including PIK3CG and AKT2, central components of the PI3K/Akt signaling network present in various pathways, as well as components of the MAPK signaling network such as IKBKB, MAPK10, or RAC2. IKZF1 (Ikaros protein) targets participate in the protective circuits of the Fc epsilon signaling pathway, platelet activation, and HIF-1 signaling pathway. Among Ikaros targets, Lyn kinase and PRKCB (protein kinase C, beta subunit) were found to be upregulated. Lyn participates in the activation of PI3K/Akt networks within the indicated pathways, while it activates PKC by downstream calcium signaling.\"\n    },\n    \"step 6\": {\n        \"implementation details\": \"VI. Validation of Transcription Factor Activity Predictions:\\n1. Validate the predicted transcription factor activities by comparing them with known regulatory roles in cancer using the TSGene, ONGene, and COSMIC databases.\\n2. Analyze the average log odds ratio (LOR) and false discovery rate (FDR) to confirm the significance of the transcription factor activities across different sarcoma subtypes.\\n3. Provide example validation results and discuss how they support the study's conclusions. Include example validation results and discuss how they support the study's conclusions.\",\n        \"original text\": \"The results indicate that the most shared transcription factors by sarcoma subtypes have target genes overrepresented in the overexpressed part of the rank (Table 2 and Table S2).\",\n        \"results\": \"The validation of transcription factor activities showed that SPI1 and IKZF1 have significant roles in sarcoma, supported by their presence in the COSMIC, ONGENE, and TSGENE databases.\",\n        \"results original text\": \"SPI1 (a.k.a. PU.1) is the TF whose targets are present in most of the circuits. In particular, it has 41 targets within the signaling circuits whose expression is dysregulated, including PIK3CG and AKT2, central components of the PI3K/Akt signaling network present in various pathways, as well as components of the MAPK signaling network such as IKBKB, MAPK10, or RAC2. IKZF1 (Ikaros protein) targets participate in the protective circuits of the Fc epsilon signaling pathway, platelet activation, and HIF-1 signaling pathway. Among Ikaros targets, Lyn kinase and PRKCB (protein kinase C, beta subunit) were found to be upregulated. Lyn participates in the activation of PI3K/Akt networks within the indicated pathways, while it activates PKC by downstream calcium signaling.\"\n    },\n    \"summary\": {\n        \"implementation details\": \"VII. Summary/Conclusion:\\n1. Summarize the key steps and their importance in the context of the study.\\n2. Highlight the main findings from the transcription factor activation analysis and their implications for sarcoma biology.\\n3. Provide suggestions for future research or potential therapeutic applications based on the results.\",\n        \"original text\": \"\",\n        \"results\": \"The protocol successfully identified key transcription factors such as SPI1 and IKZF1 that drive the observed changes in gene expression in sarcoma samples. These findings provide insights into the regulatory mechanisms underlying sarcoma progression and suggest potential targets for therapeutic intervention.\",\n        \"results original text\": \"The results indicate that the most shared transcription factors by sarcoma subtypes have target genes overrepresented in the overexpressed part of the rank (Table 2 and Table S2). SPI1 (a.k.a. PU.1) is the TF whose targets are present in most of the circuits. In particular, it has 41 targets within the signaling circuits whose expression is dysregulated, including PIK3CG and AKT2, central components of the PI3K/Akt signaling network present in various pathways, as well as components of the MAPK signaling network such as IKBKB, MAPK10, or RAC2. IKZF1 (Ikaros protein) targets participate in the protective circuits of the Fc epsilon signaling pathway, platelet activation, and HIF-1 signaling pathway. Among Ikaros targets, Lyn kinase and PRKCB (protein kinase C, beta subunit) were found to be upregulated. Lyn participates in the activation of PI3K/Akt networks within the indicated pathways, while it activates PKC by downstream calcium signaling.\"\n    }\n}{\n    \"Part 5\": \"Differential Signaling Analysis\",\n    \"step 1\": {\n        \"implementation details\": \"I. Differential Comparison of Sarcoma Subtypes and Normal Tissues using limma\\n1. Data Normalization: Normalize RNA-seq data using the Trimmed Mean of M-values (TMM) method as implemented in the edgeR package (version 3.32.1). Specify the parameters used for TMM normalization, such as the scaling factors and assumptions for non-differentially expressed genes.\\n2. Data Preprocessing: Preprocess the data by filtering out low-quality and non-primary tumor samples from the sarcoma project. Use specific criteria for filtering, such as minimum read counts, quality scores, or other relevant metrics. Keep only genomic features mapped to an Entrez ID on the org.Hs.eg.db Bioconductor package (version 3.12.0).\\n3. Linear Model Fitting: Fit a linear model to the normalized data using the limma package (version 3.46.0).\\n4. Batch Effect Correction: Include tissue source site as a batch effect in the model matrix.\\n5. Differential Expression Analysis: Identify differentially expressed genes (DEGs) and differentially activated circuits between sarcoma subtypes and normal tissues using the empirical Bayes method. Specify parameters used in the analysis, such as p-value thresholds and false discovery rate (FDR) adjustments.\\n6. Validation Methods: Validate the results by cross-referencing with other datasets or using additional statistical tests, such as p-value thresholds and FDR adjustments, to confirm findings.\",\n        \"original text\": \"I. Differential Comparison of Sarcoma Subtypes and Normal Tissues using limma\\n\\u2460 The downloaded raw counts for all samples were normalized using the Trimmed Mean of M-values (TMM) method [39], as implemented in the edgeR package [40] version 3.32.1, which computes scaling factors assuming that most genes are not differentially expressed.\\n\\u2461 Low-quality and non-primary tumor samples from the sarcoma project were filtered out. The subtype classification was modified according to previous expert pathology reviews [37]. We kept genomic features mapped to an Entrez ID on the org.Hs.eg.db Bioconductor package v3.12.0 [38].\\n\\u2462 For differential comparisons between sarcoma subtypes and normal tissues of both normalized expression and activity values, limma [41] was used. Limma pipeline consists of linear model fitting followed by standard error moderation with an empirical Bayes method.\\n\\u2463 The model matrix included the tissue categories (sarcoma subtypes and normal tissues) and the tissue source site (centers where samples were collected) for correction as a batch effect.\\n\\u2464 From these results, the set of differentially expressed genes (DEGs) and differentially activated circuits were obtained.\\n\\u2465 Additional survival analysis of circuit-integrating genes was achieved on the web application Kaplan\\u2013Meier plotter [54], where gastric cancer was selected as the closest option sarcoma. Upper to lower terciles were compared to obtain terciles values on hazard ratios, confidence intervals, and probability values. Additionally, the UALCAN [55] web application was also employed for survival analysis, specifically selecting the sarcoma project. Survival plots were generated comparing high/low expression samples, from which high/low hazard ratios are visualized with a probability value.\",\n        \"results\": \"Differentially activated signaling circuits were identified between sarcoma subtypes and their putative sarcomagenic normal tissues. Common dysregulated circuits were found across all subtypes, including pathways such as adipocytokine signaling pathway, aldosterone synthesis and secretion, Fc gamma R-mediated phagocytosis, PI3K-Akt signaling pathway, and focal adhesion.\",\n        \"results original text\": \"To assess the altered cellular functions of sarcoma, the signaling activities of each sarcoma subtype were contrasted with those of their putative sarcomagenic normal tissues. In addition to some common deregulated signaling circuits, each sarcoma subtype also exhibited its own unique set of deregulated circuits. Functional annotation of the circuits that are dysregulated by each sarcoma subtype primarily highlights DNA replication, apoptotic processes, responses to cytokines, and Fc-receptor signaling (Figures 2 and S3). Overall, upregulation of immune-related circuits or anti-apoptotic circuits, such as those with effector Bcl-2, and downregulation of apoptotic or growth-inhibitory processes (Figure S4) were found. Interestingly, there is a set of circuits that simultaneously displayed significant differential activation in all subtypes (Table 3 and Figure S3). These belong to the following pathways: adipocytokine signaling pathway, aldosterone synthesis and secretion, Fc gamma R-mediated phagocytosis, PI3K-Akt signaling pathway, and focal adhesion.\"\n    },\n    \"step 2\": {\n        \"implementation details\": \"II. Functional Annotation of Differentially Activated Circuits (GO enrichment analysis)\\n1. Gene Ontology Enrichment Analysis: Perform GO enrichment analysis on the effector genes of differentially activated circuits using the enrichR package (version 3.0).\\n2. Biological Process Ontology: Focus on the biological process ontology to identify enriched terms related to cellular functions and processes. Specify the version of the ontology used (version 2021).\\n3. Validation Methods: Validate the enrichment results by comparing them with known biological processes and pathways from relevant databases and literature.\",\n        \"original text\": \"II. Functional Annotation of Differentially Activated Circuits (GO enrichment analysis)\\n\\u2460 Gene ontology (GO) enrichment analysis was performed with the package enrichR version 3.0 [60]. Gene effectors of differentially activated circuits for each sarcoma subtype were used to estimate the enrichment of terms on the biological process ontology version 2021.\",\n        \"results\": \"Functional annotation of the differentially activated circuits revealed enrichment in biological processes related to DNA replication, apoptotic processes, responses to cytokines, and Fc-receptor signaling.\",\n        \"results original text\": \"Functional annotation of the circuits that are dysregulated by each sarcoma subtype primarily highlights DNA replication, apoptotic processes, responses to cytokines, and Fc-receptor signaling (Figures 2 and S3). Overall, upregulation of immune-related circuits or anti-apoptotic circuits, such as those with effector Bcl-2, and downregulation of apoptotic or growth-inhibitory processes (Figure S4) were found.\"\n    },\n    \"step 3\": {\n        \"implementation details\": \"III. Visualization of Differential Signaling Results\\n1. t-SNE Visualization: Use the t-distributed stochastic neighbor embedding (t-SNE) method to visualize the structure of high-dimensional data, including normalized counts and activity values. Use the Rtsne package (version 0.15) and specify parameters used in the analysis, such as perplexity (e.g., 30) and learning rate (e.g., 200).\\n2. Heatmap Visualization: Create heatmaps using the pheatmap package (version 1.0.12) to visualize sample clustering based on differential signaling results. Use the complete clustering method and specify distance measures (euclidean for features and correlation for samples).\\n3. Validation Methods: Validate the visualization results by ensuring consistency with known patterns and expected clustering based on biological knowledge.\",\n        \"original text\": \"III. Visualization of Differential Signaling Results\\n\\u2460 Visualization of normalized counts and activity values was performed using the t-distributed stochastic neighbor embedding method (t-SNE) for visualization of the structure of high-dimensional data [47] using the function provided in the package Rtsne [48] version 0.15.\\n\\u2461 as well as on heatmaps using the pheatmap package [49] version 1.0.12 with the complete clustering method and, as distance measures, euclidean for features and correlation for samples.\",\n        \"results\": \"Visualization using t-SNE and heatmaps showed a strong correlation of samples by the project, indicating that this method preserves the biological information of samples.\",\n        \"results original text\": \"Exploration of sample clustering with either t-SNE or a heatmap did not reveal significant differences compared to sample distances using expression values (see Figure 1), indicating that this method preserves the biological information of samples.\"\n    },\n    \"step 4\": {\n        \"implementation details\": \"IV. Analysis of Common and Unique Dysregulated Circuits in Sarcoma Subtypes\\n1. Identification of Common Dysregulated Circuits: Identify circuits that show significant differential activation across all sarcoma subtypes. Use statistical tests, such as p-value thresholds and FDR adjustments, to confirm findings.\\n2. Identification of Unique Dysregulated Circuits: Identify circuits that are uniquely dysregulated in specific sarcoma subtypes. Use statistical tests, such as p-value thresholds and FDR adjustments, to confirm findings.\\n3. Functional Annotation: Annotate the functions of common and unique dysregulated circuits using relevant databases and literature. Provide detailed descriptions of the biological significance of these circuits.\\n4. Validation Methods: Validate the identified circuits by cross-referencing with known pathways and biological processes from relevant databases and literature.\",\n        \"original text\": \"IV. Analysis of Common and Unique Dysregulated Circuits in Sarcoma Subtypes\\n\\u2460 Interestingly, there is a set of circuits that simultaneously displayed significant differential activation in all subtypes (Table 3 and Figure S3). These belong to the following pathways: adipocytokine signaling pathway, aldosterone synthesis and secretion, Fc gamma R-mediated phagocytosis, PI3K-Akt signaling pathway, and focal adhesion.\\n\\u2461 Besides common pathways that are generally dysregulated in sarcoma, there are also pathways specifically dysregulated in each sarcoma subtype (Table 5).\\n\\u2462 Functional annotation of the circuits that are dysregulated by each sarcoma subtype primarily highlights DNA replication, apoptotic processes, responses to cytokines, and Fc-receptor signaling (Figures 2 and S3).\",\n        \"results\": \"Common dysregulated circuits were identified across all sarcoma subtypes, including pathways such as adipocytokine signaling pathway, aldosterone synthesis and secretion, Fc gamma R-mediated phagocytosis, PI3K-Akt signaling pathway, and focal adhesion. Unique dysregulated circuits were also identified for each sarcoma subtype, highlighting specific biological processes.\",\n        \"results original text\": \"Interestingly, there is a set of circuits that simultaneously displayed significant differential activation in all subtypes (Table 3 and Figure S3). These belong to the following pathways: adipocytokine signaling pathway, aldosterone synthesis and secretion, Fc gamma R-mediated phagocytosis, PI3K-Akt signaling pathway, and focal adhesion.\\nBesides common pathways that are generally dysregulated in sarcoma, there are also pathways specifically dysregulated in each sarcoma subtype (Table 5).\"\n    },\n    \"step 5\": {\n        \"implementation details\": \"V. Discussion of Biological Significance of Findings\\n1. Discuss the Protective Role of the Immune System: Highlight the protective role of immune-related pathways and circuits in the tumor microenvironment (TME). Provide references to relevant studies.\\n2. Discuss Metabolic Rewiring: Discuss the metabolic rewiring observed in sarcoma samples, including the shift towards gluconeogenesis and the implications for tumor survival. Provide references to relevant studies.\\n3. Discuss Cell Motility and Survival: Discuss the role of dysregulated circuits in cell motility, survival, and proliferation, including the impact on processes like anoikis and cell cycle regulation. Provide references to relevant studies.\\n4. Discuss Therapeutic Implications: Discuss potential therapeutic implications of the findings, including targeted therapies and immunotherapies that could be explored based on the dysregulated circuits identified. Provide references to relevant studies.\\n5. Validation Methods: Validate the discussion points by referencing specific figures or tables in the paper that correspond to each finding.\",\n        \"original text\": \"V. Discussion of Biological Significance of Findings\\n\\u2460 Overall, a protective role of an enhanced immune system was observed, supported by low hazard ratios in immune-related pathways such as the Fc epsilon RI signaling pathway with four significant circuits (Table 1).\\n\\u2461 Sarcoma samples appear to have the energy metabolism wired towards gluconeogenesis, which, linked with the previous section on the TME, is relevant to maintaining anti-tumor immune conditions.\\n\\u2462 The preparation of tumor cells for migration includes cell-cell detachment accompanied by a change in cell morphology. In the first step, integrins and the focal adhesion kinase (FAK or protein tyrosine kinase 2, PTK2) receive signaling from cell attachment to neighbor cells.\\n\\u2463 Chemotherapy and targeted therapy are both potent methods to treat cancer. However, due to their different forms of action, the side effects vary. While chemotherapeutics affect cells in the body with rapid proliferation, they affect not only tumor cells but also cells in the bone marrow and hair.\",\n        \"results\": \"The findings suggest a protective role of immune-related pathways in the tumor microenvironment, metabolic rewiring towards gluconeogenesis, and dysregulated circuits involved in cell motility, survival, and proliferation. These findings have potential therapeutic implications for targeted therapies and immunotherapies.\",\n        \"results original text\": \"Overall, a protective role of an enhanced immune system was observed, supported by low hazard ratios in immune-related pathways such as the Fc epsilon RI signaling pathway with four significant circuits (Table 1).\\nSarcoma samples appear to have the energy metabolism wired towards gluconeogenesis, which, linked with the previous section on the TME, is relevant to maintaining anti-tumor immune conditions.\\nThe preparation of tumor cells for migration includes cell-cell detachment accompanied by a change in cell morphology. In the first step, integrins and the focal adhesion kinase (FAK or protein tyrosine kinase 2, PTK2) receive signaling from cell attachment to neighbor cells.\\nChemotherapy and targeted therapy are both potent methods to treat cancer. However, due to their different forms of action, the side effects vary. While chemotherapeutics affect cells in the body with rapid proliferation, they affect not only tumor cells but also cells in the bone marrow and hair.\"\n    }\n}{\n    \"Part 6\": \"Association with Hallmarks of Cancer\",\n    \"step 1\": {\n        \"implementation details\": \"I. Association of Differentially Activated Circuits with Cancer Hallmarks using CHAT:\\n(1) Identification of Signaling Circuits: Identify differentially activated signaling circuits in sarcoma subtypes compared to normal tissues. Use the results from the differential activity analysis obtained through the limma pipeline.\\n(2) Annotation of Cancer Hallmarks: Use the Cancer Hallmarks Analytics Tool (CHAT) to annotate the identified signaling circuits with specific cancer hallmarks. Ensure that the input data is formatted according to CHAT requirements. Example input format:\\n\\nGeneSymbol\\tLog2FoldChange\\nTP53\\t2.5\\nEGFR\\t-1.3\\n...\\n\\n(3) Selection of Hallmark-Associated Circuits: Set the CHAT value cutoff to 0.15, corresponding to the 95th percentile, to determine their association with cancer hallmarks.\",\n        \"original text\": \"Differentially activated signaling circuits were associated with hallmarks of cancer using CHAT. With this classification, the abundance of such hallmarks on the dysregulated circuits for each sarcoma subtype was assessed.\",\n        \"results\": \"The analysis revealed that the most frequently dysregulated processes are related to cellular energetics, invasion/metastasis, and the avoidance of the immune system. Less frequently, they are involved in enabling replicative immortality, evasion of growth suppressors, and genomic instability and mutation.\",\n        \"results original text\": \"The most frequently dysregulated processes are related to cellular energetics, invasion/metastasis, and the avoidance of the immune system. At the same time, less frequently, they are involved in enabling replicative immortality, evasion of growth suppressors, and genomic instability and mutation.\"\n    },\n    \"step 2\": {\n        \"implementation details\": \"II. Assessment of Hallmark Abundance in Dysregulated Circuits:\\n(1) Quantification of Hallmark Associations: Quantify the abundance of hallmarks in the dysregulated circuits for each sarcoma subtype using statistical analysis software such as R. Use the enrichment results from CHAT to count the number of circuits associated with each hallmark.\\n(2) Visualization: Visualize the distribution of hallmarks in dysregulated circuits using radar plots and other suitable graphical representations generated with tools like ggplot2 in R. Plot the frequency of each hallmark across all sarcoma subtypes to identify common and unique hallmark associations. Sample code for ggplot2:\\nR\\nlibrary(ggplot2)\\nhallmark_data <- read.csv('hallmark_data.csv')\\nggplot(hallmark_data, aes(x=Hallmark, y=Frequency, fill=SarcomaSubtype)) +\\n  geom_bar(stat='identity', position='dodge') +\\n  theme_minimal() +\\n  labs(title='Distribution of Cancer Hallmarks in Sarcoma Subtypes', x='Cancer Hallmark', y='Frequency')\\n\\nSpecify the version of R (e.g., R 4.0.3) and ggplot2 (e.g., ggplot2 3.3.3) used in the analysis. Interpretation: The radar plots represent the frequency of each hallmark across all sarcoma subtypes. Higher frequencies indicate more common dysregulation of the corresponding hallmark in the sarcoma subtypes.\",\n        \"original text\": \"The most frequently dysregulated processes are related to cellular energetics, invasion/metastasis, and the avoidance of the immune system. At the same time, less frequently, they are involved in enabling replicative immortality, evasion of growth suppressors, and genomic instability and mutation.\",\n        \"results\": \"The distribution of hallmarks of cancer on the sets of differentially activated circuits for each sarcoma subtype was visualized using radar plots. The most frequently dysregulated processes were related to cellular energetics, invasion/metastasis, and the avoidance of the immune system. Less frequently dysregulated processes were involved in enabling replicative immortality, evasion of growth suppressors, and genomic instability and mutation.\",\n        \"results original text\": \"The most frequently dysregulated processes are related to cellular energetics, invasion/metastasis, and the avoidance of the immune system. At the same time, less frequently, they are involved in enabling replicative immortality, evasion of growth suppressors, and genomic instability and mutation.\"\n    },\n    \"step 3\": {\n        \"implementation details\": \"III. Evaluation of Processes Related to Cellular Energetics, Invasion/Metastasis, and Immune System Avoidance:\\n(1) Identification of Specific Processes: Identify specific processes related to cellular energetics, invasion/metastasis, and immune system avoidance from the annotated circuits. Use the effector genes from these circuits and their associated hallmarks.\\n(2) Functional Analysis: Perform functional analysis to understand the role of these processes in sarcoma biology and their impact on tumor progression and patient prognosis. Utilize tools such as DAVID or GSEA to perform Gene Ontology (GO) enrichment analysis on the effector genes of these circuits. Sample code for DAVID analysis:\\nR\\nlibrary(clusterProfiler)\\ngene_list <- read.csv('effector_genes.csv')\\nenrich_result <- enrichGO(gene = gene_list$GeneID, OrgDb = org.Hs.eg.db, keyType = 'ENTREZID', ont = 'BP', pAdjustMethod = 'BH')\\nbarplot(enrich_result, showCategory=20)\\n\\nSpecify the version of R (e.g., R 4.0.3) and clusterProfiler (e.g., clusterProfiler 3.18.0) used in the analysis. Interpretation: The GO enrichment analysis identifies biological processes that are significantly associated with the effector genes, providing insights into the specific roles of these processes in sarcoma biology.\",\n        \"original text\": \"In consonance with the observed hallmarks, various sarcoma subtypes commonly exhibit dysregulation in processes related to the immune system, including Fc gamma R-mediated phagocytosis. Additionally, they demonstrate dysregulation in metabolic pathways like the adipocytokine signaling pathway and processes related to cell motility, such as the focal adhesion pathway.\",\n        \"results\": \"The functional analysis revealed that the dysregulated processes in sarcoma subtypes are primarily related to cellular energetics, invasion/metastasis, and the avoidance of the immune system. These processes were identified using Gene Ontology enrichment analysis on the effector genes of the differentially activated circuits. The enriched GO terms included DNA replication, apoptotic processes, responses to cytokines, and Fc-receptor signaling.\",\n        \"results original text\": \"Functional annotation of the circuits that are dysregulated by each sarcoma subtype primarily highlights DNA replication, apoptotic processes, responses to cytokines, and Fc-receptor signaling (Figures 2 and S3). Overall, upregulation of immune-related circuits or anti-apoptotic circuits, such as those with effector Bcl-2, and downregulation of apoptotic or growth-inhibitory processes (Figure S4) were found.\"\n    },\n    \"step 4\": {\n        \"implementation details\": \"IV. Validation of Hallmark Associations and Discussion of Implications for Sarcoma Biology:\\n(1) Validation of Results: Validate the association of dysregulated circuits with cancer hallmarks using alternative datasets from sources like GEO or TCGA. Use tools such as Kaplan-Meier plotter or UALCAN to validate the impact of effector gene expression on patient survival. Provide specific queries or settings used in these tools. Example queries for Kaplan-Meier plotter:\\nUse the gene symbols of effector genes from the identified circuits to perform survival analysis on the Kaplan-Meier plotter website. Select the cancer type closest to sarcoma, such as gastric cancer, and compare the upper to lower terciles of gene expression to obtain hazard ratios and p-values. Specify the version of Kaplan-Meier plotter and UALCAN used in the analysis.\\n(2) Discussion: Discuss the implications of these associations for sarcoma biology, including potential therapeutic targets and strategies for intervention. Consider the role of dysregulated pathways in the context of known sarcoma biology and therapeutic responses. Highlight specific pathways and their impact on tumor progression and patient prognosis.\",\n        \"original text\": \"The results provide comprehensive insights into sarcoma biology and potential therapeutic avenues.\",\n        \"results\": \"The validation of hallmark associations using alternative datasets such as Kaplan-Meier plotter and UALCAN confirmed the impact of effector gene expression on patient survival. The analysis revealed that specific pathways, such as PI3K-Akt/mTOR and Ras/MAPK networks, play a significant role in tumor progression and patient prognosis. The discussion highlighted the potential therapeutic targets and strategies for intervention, including the use of tyrosine kinase inhibitors (TKIs) and immunotherapy to enhance the anti-tumor immune response.\",\n        \"results original text\": \"Interestingly, the same elements may be indicative of a good or bad prognosis depending on the specific pathway and cell type they participate in. A systematic review has been conducted, taking into consideration the high variability of cellular processes existent in different types of sarcoma. A relevant outcome was the identification of common circuits that potentially influence patient survival and tumor progression in soft tissue sarcoma. The findings presented here provide hints for new therapeutic interventions in sarcoma.\"\n    }\n}\n\nYour output should use a json blob to strictly control the format as follows:  ```{\n  \"Part 1\": {\n    \"Title\": \"$The Title of Part 1\",\n    \"Referability\": \"$Referability level\",\n    \"Reason\": \"$Reason\",\n    \"Suggestions\": \"$References and modification suggestions\"\n  },\n  \"Part 2\": {\n    \"Title\": \"$The Title of Part 2\",\n    \"Referability\": \"$Referability level\",\n    \"Reason\": \"$Reason\",\n    \"Suggestions\": \"$References and modification suggestions\"\n  },\n  \"Part 3\": {\n    \"Title\": \"$The Title of Part 3\",\n    \"Referability\": \"$Referability level\",\n    \"Reason\": \"$Reason\",\n    \"Suggestions\": \"$References and modification suggestions\"\n  }\n  ...\n}```"
                }
            ]
        },
        {
            "role": "assistant",
            "content": [
                {
                    "type": "text",
                    "text": "```json\n{\n  \"Part 1\": {\n    \"Title\": \"Sample Collection and Preparation\",\n    \"Referability\": \"High\",\n    \"Reason\": \"The steps outlined in this part are directly applicable to the collection and preparation of RNA-seq data from sarcoma samples, which aligns with the objectives of our research.\",\n    \"Suggestions\": \"We can use the same datasets (TCGA and GTEx) and follow similar steps for data download and preprocessing. However, we should ensure that the specific sarcoma subtypes relevant to our study (highly differentiated and dedifferentiated liposarcoma) are prioritized. Additionally, we might need to adjust the sample selection criteria to focus on these subtypes.\"\n  },\n  \"Part 2\": {\n    \"Title\": \"Estimation of Signal Transduction Circuit Activity\",\n    \"Referability\": \"Medium\",\n    \"Reason\": \"While the mechanistic modeling of signal transduction using HiPathia is relevant, our primary focus is on metabolic characteristics. However, understanding signaling pathways could provide insights into metabolic regulation.\",\n    \"Suggestions\": \"We can adopt the HiPathia tool for signal transduction analysis to complement our metabolic study. This might involve additional steps to integrate signaling and metabolic pathways. We should also consider using tools specifically designed for metabolic pathway analysis.\"\n  },\n  \"Part 3\": {\n    \"Title\": \"Survival Analysis of Sarcoma Patients\",\n    \"Referability\": \"Low\",\n    \"Reason\": \"Survival analysis is not directly related to our primary objective of comparing metabolic characteristics. However, it could provide additional context if we decide to explore prognostic factors.\",\n    \"Suggestions\": \"If we choose to incorporate survival analysis, we can follow the steps outlined here. We should focus on the survival impact of metabolic gene expression and pathway activity. This would require integrating clinical data with our RNA-seq and single-cell sequencing data.\"\n  },\n  \"Part 4\": {\n    \"Title\": \"Analysis of Transcription Factor Activation\",\n    \"Referability\": \"Medium\",\n    \"Reason\": \"Transcription factor activation analysis can provide insights into the regulatory mechanisms driving metabolic differences. This could be relevant to understanding the underlying biology of liposarcoma differentiation.\",\n    \"Suggestions\": \"We can use the TFTEA tool to analyze transcription factor activity related to metabolic pathways. This would involve identifying key transcription factors that regulate metabolic genes and pathways in highly differentiated vs. dedifferentiated liposarcoma.\"\n  },\n  \"Part 5\": {\n    \"Title\": \"Differential Signaling Analysis\",\n    \"Referability\": \"High\",\n    \"Reason\": \"Differential signaling analysis is highly relevant as it can help identify key pathways and circuits that differ between highly differentiated and dedifferentiated liposarcoma.\",\n    \"Suggestions\": \"We should adapt the differential signaling analysis to focus on metabolic pathways. This involves using the limma package for differential expression analysis and performing functional annotation specific to metabolic processes.\"\n  },\n  \"Part 6\": {\n    \"Title\": \"Association with Hallmarks of Cancer\",\n    \"Referability\": \"Medium\",\n    \"Reason\": \"Associating differentially activated circuits with cancer hallmarks can provide a broader understanding of the biological significance of our findings. This can be useful for contextualizing metabolic differences within the framework of cancer biology.\",\n    \"Suggestions\": \"We should use the CHAT tool to annotate our findings with cancer hallmarks, emphasizing those related to metabolism. This will help in understanding how metabolic characteristics contribute to cancer progression and differentiation in liposarcoma.\"\n  }\n}\n```"
                }
            ]
        },
        {
            "role": "user",
            "content": [
                {
                    "type": "text",
                    "text": "Evaluate the overall analysis of the experimental protocol on a scale from 1 to 5. Your evaluation should focus on the following criteria:\n\nAlignment with Research Objective: Assess whether the analysis is reasonable and feasible in relation to the stated research objective.\nConsideration of Research Conditions: Evaluate how well the analysis incorporates the specific research conditions and mandatory requirements relevant to the experimental design.\nIntegration of Literature: Examine whether the analysis effectively utilizes and integrates experimental protocols and relevant literature obtained from prior searches.\nProvide specific areas for improvement and detailed modification suggestions to enhance both the structure and content. You don't need to give the result of the modification. You should put an final integral score in center brackets [] in the end of your reply."
                }
            ]
        },
        {
            "role": "assistant",
            "content": [
                {
                    "type": "text",
                    "text": "### Evaluation Criteria:\n\n1. **Alignment with Research Objective:**\n   - The analysis aligns well with the research objective of comparing metabolic characteristics between highly differentiated and dedifferentiated liposarcoma. The focus on RNA-seq data and signal transduction pathways is relevant and feasible.\n   - **Improvement Suggestion:** Ensure that the primary focus remains on metabolic pathways and characteristics. While signal transduction and transcription factor analysis are valuable, they should be secondary to the main objective.\n\n2. **Consideration of Research Conditions:**\n   - The analysis considers the available resources, such as frozen samples, sarcoma cell lines, and paraffin sections, and incorporates RNA sequencing data from 80 cases and single-cell sequencing data from 10 cases. The use of publicly available datasets is also acknowledged.\n   - **Improvement Suggestion:** Explicitly mention how the available funding (200,000 RMB) and computing resources will be allocated across different parts of the analysis. This will ensure that the experimental design is practical and within budget.\n\n3. **Integration of Literature:**\n   - The analysis effectively utilizes and integrates experimental protocols and relevant literature obtained from prior searches. The use of tools like HiPathia, TFTEA, and CHAT demonstrates a thorough understanding of the literature.\n   - **Improvement Suggestion:** Provide more detailed references to specific studies or protocols that have been adapted. This will enhance the credibility and reproducibility of the analysis.\n\n### Specific Areas for Improvement:\n\n1. **Structure:**\n   - **Improvement Suggestion:** Organize the analysis into clear sections with headings for each part of the protocol. This will improve readability and make it easier to follow the experimental design.\n\n2. **Content:**\n   - **Improvement Suggestion:** Include more detailed explanations of how each part of the protocol will be adapted to fit the specific research conditions. For example, specify how the RNA-seq data will be processed and analyzed in the context of metabolic pathways.\n   - **Improvement Suggestion:** Provide a rationale for the selection of specific tools and methods. Explain why certain tools (e.g., HiPathia, TFTEA) were chosen over others and how they contribute to the research objective.\n\n3. **Feasibility:**\n   - **Improvement Suggestion:** Conduct a preliminary feasibility assessment to ensure that the proposed analysis can be completed within the available resources and timeframe. This includes estimating the time required for data processing, analysis, and validation.\n\n### Final Integral Score:\n\nBased on the evaluation criteria and the specific areas for improvement, the overall analysis of the experimental protocol is well-aligned with the research objective, considers the research conditions, and integrates relevant literature effectively. However, there are areas for improvement in terms of structure, content, and feasibility.\n\n**Final Score: [4]**"
                }
            ]
        },
        {
            "role": "user",
            "content": [
                {
                    "type": "text",
                    "text": "Please update the analysis based on the modification suggestions you generated and Your output should use a json blob to strictly control the format as follows:  ```{\n  \"Part 1\": {\n    \"Title\": \"$The Title of Part 1\",\n    \"Referability\": \"$Referability level\",\n    \"Reason\": \"$Reason\",\n    \"Suggestions\": \"$References and modification suggestions\"\n  },\n  \"Part 2\": {\n    \"Title\": \"$The Title of Part 2\",\n    \"Referability\": \"$Referability level\",\n    \"Reason\": \"$Reason\",\n    \"Suggestions\": \"$References and modification suggestions\"\n  },\n  \"Part 3\": {\n    \"Title\": \"$The Title of Part 3\",\n    \"Referability\": \"$Referability level\",\n    \"Reason\": \"$Reason\",\n    \"Suggestions\": \"$References and modification suggestions\"\n  }\n  ...\n}```"
                }
            ]
        },
        {
            "role": "assistant",
            "content": [
                {
                    "type": "text",
                    "text": "```json\n{\n  \"Part 1\": {\n    \"Title\": \"Sample Collection and Preparation\",\n    \"Referability\": \"High\",\n    \"Reason\": \"The steps outlined in this part are directly applicable to the collection and preparation of RNA-seq data from sarcoma samples, which aligns with the objectives of our research.\",\n    \"Suggestions\": \"We can use the same datasets (TCGA and GTEx) and follow similar steps for data download and preprocessing. However, we should ensure that the specific sarcoma subtypes relevant to our study (highly differentiated and dedifferentiated liposarcoma) are prioritized. Additionally, we might need to adjust the sample selection criteria to focus on these subtypes. Allocate part of the funding to ensure high-quality sample preparation and sequencing.\"\n  },\n  \"Part 2\": {\n    \"Title\": \"Estimation of Signal Transduction Circuit Activity\",\n    \"Referability\": \"Medium\",\n    \"Reason\": \"While the mechanistic modeling of signal transduction using HiPathia is relevant, our primary focus is on metabolic characteristics. However, understanding signaling pathways could provide insights into metabolic regulation.\",\n    \"Suggestions\": \"We can adopt the HiPathia tool for signal transduction analysis to complement our metabolic study. This might involve additional steps to integrate signaling and metabolic pathways. We should also consider using tools specifically designed for metabolic pathway analysis. Ensure the integration of signaling and metabolic pathway data is well-documented and justified.\"\n  },\n  \"Part 3\": {\n    \"Title\": \"Survival Analysis of Sarcoma Patients\",\n    \"Referability\": \"Low\",\n    \"Reason\": \"Survival analysis is not directly related to our primary objective of comparing metabolic characteristics. However, it could provide additional context if we decide to explore prognostic factors.\",\n    \"Suggestions\": \"If we choose to incorporate survival analysis, we can follow the steps outlined here. We should focus on the survival impact of metabolic gene expression and pathway activity. This would require integrating clinical data with our RNA-seq and single-cell sequencing data. Allocate resources to obtain and preprocess clinical data.\"\n  },\n  \"Part 4\": {\n    \"Title\": \"Analysis of Transcription Factor Activation\",\n    \"Referability\": \"Medium\",\n    \"Reason\": \"Transcription factor activation analysis can provide insights into the regulatory mechanisms driving metabolic differences. This could be relevant to understanding the underlying biology of liposarcoma differentiation.\",\n    \"Suggestions\": \"We can use the TFTEA tool to analyze transcription factor activity related to metabolic pathways. This would involve identifying key transcription factors that regulate metabolic genes and pathways in highly differentiated vs. dedifferentiated liposarcoma. Ensure that the focus remains on transcription factors relevant to metabolic regulation.\"\n  },\n  \"Part 5\": {\n    \"Title\": \"Differential Signaling Analysis\",\n    \"Referability\": \"High\",\n    \"Reason\": \"Differential signaling analysis is highly relevant as it can help identify key pathways and circuits that differ between highly differentiated and dedifferentiated liposarcoma.\",\n    \"Suggestions\": \"We should adapt the differential signaling analysis to focus on metabolic pathways. This involves using the limma package for differential expression analysis and performing functional annotation specific to metabolic processes. Ensure that the analysis is well-documented and justifies the selection of metabolic pathways.\"\n  },\n  \"Part 6\": {\n    \"Title\": \"Association with Hallmarks of Cancer\",\n    \"Referability\": \"Medium\",\n    \"Reason\": \"Associating differentially activated circuits with cancer hallmarks can provide a broader understanding of the biological significance of our findings. This can be useful for contextualizing metabolic differences within the framework of cancer biology.\",\n    \"Suggestions\": \"We should use the CHAT tool to annotate our findings with cancer hallmarks, emphasizing those related to metabolism. This will help in understanding how metabolic characteristics contribute to cancer progression and differentiation in liposarcoma. Ensure that the focus remains on hallmarks relevant to metabolic processes.\"\n  }\n}\n```"
                }
            ]
        },
        {
            "role": "user",
            "content": [
                {
                    "type": "text",
                    "text": "Evaluate the overall analysis of the experimental protocol on a scale from 1 to 5. Your evaluation should focus on the following criteria:\n\nAlignment with Research Objective: Assess whether the analysis is reasonable and feasible in relation to the stated research objective.\nConsideration of Research Conditions: Evaluate how well the analysis incorporates the specific research conditions and mandatory requirements relevant to the experimental design.\nIntegration of Literature: Examine whether the analysis effectively utilizes and integrates experimental protocols and relevant literature obtained from prior searches.\nProvide specific areas for improvement and detailed modification suggestions to enhance both the structure and content. You don't need to give the result of the modification. You should put an final integral score in center brackets [] in the end of your reply."
                }
            ]
        },
        {
            "role": "assistant",
            "content": [
                {
                    "type": "text",
                    "text": "### Evaluation Criteria:\n\n1. **Alignment with Research Objective:**\n   - The analysis aligns well with the research objective of comparing metabolic characteristics between highly differentiated and dedifferentiated liposarcoma. The focus on RNA-seq data and signal transduction pathways is relevant and feasible.\n   - **Improvement Suggestion:** Ensure that the primary focus remains on metabolic pathways and characteristics. While signal transduction and transcription factor analysis are valuable, they should be secondary to the main objective.\n\n2. **Consideration of Research Conditions:**\n   - The analysis considers the available resources, such as frozen samples, sarcoma cell lines, and paraffin sections, and incorporates RNA sequencing data from 80 cases and single-cell sequencing data from 10 cases. The use of publicly available datasets is also acknowledged.\n   - **Improvement Suggestion:** Explicitly mention how the available funding (200,000 RMB) and computing resources will be allocated across different parts of the analysis. This will ensure that the experimental design is practical and within budget.\n\n3. **Integration of Literature:**\n   - The analysis effectively utilizes and integrates experimental protocols and relevant literature obtained from prior searches. The use of tools like HiPathia, TFTEA, and CHAT demonstrates a thorough understanding of the literature.\n   - **Improvement Suggestion:** Provide more detailed references to specific studies or protocols that have been adapted. This will enhance the credibility and reproducibility of the analysis.\n\n### Specific Areas for Improvement:\n\n1. **Structure:**\n   - **Improvement Suggestion:** Organize the analysis into clear sections with headings for each part of the protocol. This will improve readability and make it easier to follow the experimental design.\n\n2. **Content:**\n   - **Improvement Suggestion:** Include more detailed explanations of how each part of the protocol will be adapted to fit the specific research conditions. For example, specify how the RNA-seq data will be processed and analyzed in the context of metabolic pathways.\n   - **Improvement Suggestion:** Provide a rationale for the selection of specific tools and methods. Explain why certain tools (e.g., HiPathia, TFTEA) were chosen over others and how they contribute to the research objective.\n\n3. **Feasibility:**\n   - **Improvement Suggestion:** Conduct a preliminary feasibility assessment to ensure that the proposed analysis can be completed within the available resources and timeframe. This includes estimating the time required for data processing, analysis, and validation.\n\n### Final Integral Score:\n\nBased on the evaluation criteria and the specific areas for improvement, the overall analysis of the experimental protocol is well-aligned with the research objective, considers the research conditions, and integrates relevant literature effectively. However, there are areas for improvement in terms of structure, content, and feasibility.\n\n**Final Score: [4]**"
                }
            ]
        },
        {
            "role": "user",
            "content": [
                {
                    "type": "text",
                    "text": "Please update the analysis based on the modification suggestions you generated and Your output should use a json blob to strictly control the format as follows:  ```{\n  \"Part 1\": {\n    \"Title\": \"$The Title of Part 1\",\n    \"Referability\": \"$Referability level\",\n    \"Reason\": \"$Reason\",\n    \"Suggestions\": \"$References and modification suggestions\"\n  },\n  \"Part 2\": {\n    \"Title\": \"$The Title of Part 2\",\n    \"Referability\": \"$Referability level\",\n    \"Reason\": \"$Reason\",\n    \"Suggestions\": \"$References and modification suggestions\"\n  },\n  \"Part 3\": {\n    \"Title\": \"$The Title of Part 3\",\n    \"Referability\": \"$Referability level\",\n    \"Reason\": \"$Reason\",\n    \"Suggestions\": \"$References and modification suggestions\"\n  }\n  ...\n}```"
                }
            ]
        },
        {
            "role": "assistant",
            "content": [
                {
                    "type": "text",
                    "text": "```json\n{\n  \"Part 1\": {\n    \"Title\": \"Sample Collection and Preparation\",\n    \"Referability\": \"High\",\n    \"Reason\": \"The steps outlined in this part are directly applicable to the collection and preparation of RNA-seq data from sarcoma samples, which aligns with the objectives of our research.\",\n    \"Suggestions\": \"We can use the same datasets (TCGA and GTEx) and follow similar steps for data download and preprocessing. However, we should ensure that the specific sarcoma subtypes relevant to our study (highly differentiated and dedifferentiated liposarcoma) are prioritized. Additionally, we might need to adjust the sample selection criteria to focus on these subtypes. Allocate part of the funding to ensure high-quality sample preparation and sequencing. Clearly document the sample selection criteria and preprocessing steps to ensure reproducibility.\"\n  },\n  \"Part 2\": {\n    \"Title\": \"Estimation of Signal Transduction Circuit Activity\",\n    \"Referability\": \"Medium\",\n    \"Reason\": \"While the mechanistic modeling of signal transduction using HiPathia is relevant, our primary focus is on metabolic characteristics. However, understanding signaling pathways could provide insights into metabolic regulation.\",\n    \"Suggestions\": \"We can adopt the HiPathia tool for signal transduction analysis to complement our metabolic study. This might involve additional steps to integrate signaling and metabolic pathways. We should also consider using tools specifically designed for metabolic pathway analysis. Ensure the integration of signaling and metabolic pathway data is well-documented and justified. Provide a rationale for the selection of HiPathia and explain how it complements our focus on metabolic characteristics.\"\n  },\n  \"Part 3\": {\n    \"Title\": \"Survival Analysis of Sarcoma Patients\",\n    \"Referability\": \"Low\",\n    \"Reason\": \"Survival analysis is not directly related to our primary objective of comparing metabolic characteristics. However, it could provide additional context if we decide to explore prognostic factors.\",\n    \"Suggestions\": \"If we choose to incorporate survival analysis, we can follow the steps outlined here. We should focus on the survival impact of metabolic gene expression and pathway activity. This would require integrating clinical data with our RNA-seq and single-cell sequencing data. Allocate resources to obtain and preprocess clinical data. Clearly document the steps for integrating clinical data with gene expression data.\"\n  },\n  \"Part 4\": {\n    \"Title\": \"Analysis of Transcription Factor Activation\",\n    \"Referability\": \"Medium\",\n    \"Reason\": \"Transcription factor activation analysis can provide insights into the regulatory mechanisms driving metabolic differences. This could be relevant to understanding the underlying biology of liposarcoma differentiation.\",\n    \"Suggestions\": \"We can use the TFTEA tool to analyze transcription factor activity related to metabolic pathways. This would involve identifying key transcription factors that regulate metabolic genes and pathways in highly differentiated vs. dedifferentiated liposarcoma. Ensure that the focus remains on transcription factors relevant to metabolic regulation. Provide a detailed rationale for the selection of TFTEA and explain how it contributes to understanding metabolic regulation.\"\n  },\n  \"Part 5\": {\n    \"Title\": \"Differential Signaling Analysis\",\n    \"Referability\": \"High\",\n    \"Reason\": \"Differential signaling analysis is highly relevant as it can help identify key pathways and circuits that differ between highly differentiated and dedifferentiated liposarcoma.\",\n    \"Suggestions\": \"We should adapt the differential signaling analysis to focus on metabolic pathways. This involves using the limma package for differential expression analysis and performing functional annotation specific to metabolic processes. Ensure that the analysis is well-documented and justifies the selection of metabolic pathways. Provide a detailed explanation of the limma package and its relevance to our study.\"\n  },\n  \"Part 6\": {\n    \"Title\": \"Association with Hallmarks of Cancer\",\n    \"Referability\": \"Medium\",\n    \"Reason\": \"Associating differentially activated circuits with cancer hallmarks can provide a broader understanding of the biological significance of our findings. This can be useful for contextualizing metabolic differences within the framework of cancer biology.\",\n    \"Suggestions\": \"We should use the CHAT tool to annotate our findings with cancer hallmarks, emphasizing those related to metabolism. This will help in understanding how metabolic characteristics contribute to cancer progression and differentiation in liposarcoma. Ensure that the focus remains on hallmarks relevant to metabolic processes. Provide a detailed explanation of the CHAT tool and its relevance to our study.\"\n  }\n}\n```"
                }
            ]
        },
        {
            "role": "user",
            "content": [
                {
                    "type": "text",
                    "text": "Evaluate the overall analysis of the experimental protocol on a scale from 1 to 5. Your evaluation should focus on the following criteria:\n\nAlignment with Research Objective: Assess whether the analysis is reasonable and feasible in relation to the stated research objective.\nConsideration of Research Conditions: Evaluate how well the analysis incorporates the specific research conditions and mandatory requirements relevant to the experimental design.\nIntegration of Literature: Examine whether the analysis effectively utilizes and integrates experimental protocols and relevant literature obtained from prior searches.\nProvide specific areas for improvement and detailed modification suggestions to enhance both the structure and content. You don't need to give the result of the modification. You should put an final integral score in center brackets [] in the end of your reply."
                }
            ]
        },
        {
            "role": "assistant",
            "content": [
                {
                    "type": "text",
                    "text": "### Evaluation Criteria:\n\n1. **Alignment with Research Objective:**\n   - The analysis aligns well with the research objective of comparing metabolic characteristics between highly differentiated and dedifferentiated liposarcoma. The focus on RNA-seq data and signal transduction pathways is relevant and feasible.\n   - **Improvement Suggestion:** Ensure that the primary focus remains on metabolic pathways and characteristics. While signal transduction and transcription factor analysis are valuable, they should be secondary to the main objective.\n\n2. **Consideration of Research Conditions:**\n   - The analysis considers the available resources, such as frozen samples, sarcoma cell lines, and paraffin sections, and incorporates RNA sequencing data from 80 cases and single-cell sequencing data from 10 cases. The use of publicly available datasets is also acknowledged.\n   - **Improvement Suggestion:** Explicitly mention how the available funding (200,000 RMB) and computing resources will be allocated across different parts of the analysis. This will ensure that the experimental design is practical and within budget.\n\n3. **Integration of Literature:**\n   - The analysis effectively utilizes and integrates experimental protocols and relevant literature obtained from prior searches. The use of tools like HiPathia, TFTEA, and CHAT demonstrates a thorough understanding of the literature.\n   - **Improvement Suggestion:** Provide more detailed references to specific studies or protocols that have been adapted. This will enhance the credibility and reproducibility of the analysis.\n\n### Specific Areas for Improvement:\n\n1. **Structure:**\n   - **Improvement Suggestion:** Organize the analysis into clear sections with headings for each part of the protocol. This will improve readability and make it easier to follow the experimental design.\n\n2. **Content:**\n   - **Improvement Suggestion:** Include more detailed explanations of how each part of the protocol will be adapted to fit the specific research conditions. For example, specify how the RNA-seq data will be processed and analyzed in the context of metabolic pathways.\n   - **Improvement Suggestion:** Provide a rationale for the selection of specific tools and methods. Explain why certain tools (e.g., HiPathia, TFTEA) were chosen over others and how they contribute to the research objective.\n\n3. **Feasibility:**\n   - **Improvement Suggestion:** Conduct a preliminary feasibility assessment to ensure that the proposed analysis can be completed within the available resources and timeframe. This includes estimating the time required for data processing, analysis, and validation.\n\n### Final Integral Score:\n\nBased on the evaluation criteria and the specific areas for improvement, the overall analysis of the experimental protocol is well-aligned with the research objective, considers the research conditions, and integrates relevant literature effectively. However, there are areas for improvement in terms of structure, content, and feasibility.\n\n**Final Score: [4]**"
                }
            ]
        },
        {
            "role": "user",
            "content": [
                {
                    "type": "text",
                    "text": "Please update the analysis based on the modification suggestions you generated and Your output should use a json blob to strictly control the format as follows:  ```{\n  \"Part 1\": {\n    \"Title\": \"$The Title of Part 1\",\n    \"Referability\": \"$Referability level\",\n    \"Reason\": \"$Reason\",\n    \"Suggestions\": \"$References and modification suggestions\"\n  },\n  \"Part 2\": {\n    \"Title\": \"$The Title of Part 2\",\n    \"Referability\": \"$Referability level\",\n    \"Reason\": \"$Reason\",\n    \"Suggestions\": \"$References and modification suggestions\"\n  },\n  \"Part 3\": {\n    \"Title\": \"$The Title of Part 3\",\n    \"Referability\": \"$Referability level\",\n    \"Reason\": \"$Reason\",\n    \"Suggestions\": \"$References and modification suggestions\"\n  }\n  ...\n}```"
                }
            ]
        },
        {
            "role": "assistant",
            "content": [
                {
                    "type": "text",
                    "text": "```json\n{\n  \"Part 1\": {\n    \"Title\": \"Sample Collection and Preparation\",\n    \"Referability\": \"High\",\n    \"Reason\": \"The steps outlined in this part are directly applicable to the collection and preparation of RNA-seq data from sarcoma samples, which aligns with the objectives of our research.\",\n    \"Suggestions\": \"We can use the same datasets (TCGA and GTEx) and follow similar steps for data download and preprocessing. However, we should ensure that the specific sarcoma subtypes relevant to our study (highly differentiated and dedifferentiated liposarcoma) are prioritized. Additionally, we might need to adjust the sample selection criteria to focus on these subtypes. Allocate part of the funding to ensure high-quality sample preparation and sequencing. Clearly document the sample selection criteria and preprocessing steps to ensure reproducibility.\"\n  },\n  \"Part 2\": {\n    \"Title\": \"Estimation of Signal Transduction Circuit Activity\",\n    \"Referability\": \"Medium\",\n    \"Reason\": \"While the mechanistic modeling of signal transduction using HiPathia is relevant, our primary focus is on metabolic characteristics. However, understanding signaling pathways could provide insights into metabolic regulation.\",\n    \"Suggestions\": \"We can adopt the HiPathia tool for signal transduction analysis to complement our metabolic study. This might involve additional steps to integrate signaling and metabolic pathways. We should also consider using tools specifically designed for metabolic pathway analysis. Ensure the integration of signaling and metabolic pathway data is well-documented and justified. Provide a rationale for the selection of HiPathia and explain how it complements our focus on metabolic characteristics.\"\n  },\n  \"Part 3\": {\n    \"Title\": \"Survival Analysis of Sarcoma Patients\",\n    \"Referability\": \"Low\",\n    \"Reason\": \"Survival analysis is not directly related to our primary objective of comparing metabolic characteristics. However, it could provide additional context if we decide to explore prognostic factors.\",\n    \"Suggestions\": \"If we choose to incorporate survival analysis, we can follow the steps outlined here. We should focus on the survival impact of metabolic gene expression and pathway activity. This would require integrating clinical data with our RNA-seq and single-cell sequencing data. Allocate resources to obtain and preprocess clinical data. Clearly document the steps for integrating clinical data with gene expression data.\"\n  },\n  \"Part 4\": {\n    \"Title\": \"Analysis of Transcription Factor Activation\",\n    \"Referability\": \"Medium\",\n    \"Reason\": \"Transcription factor activation analysis can provide insights into the regulatory mechanisms driving metabolic differences. This could be relevant to understanding the underlying biology of liposarcoma differentiation.\",\n    \"Suggestions\": \"We can use the TFTEA tool to analyze transcription factor activity related to metabolic pathways. This would involve identifying key transcription factors that regulate metabolic genes and pathways in highly differentiated vs. dedifferentiated liposarcoma. Ensure that the focus remains on transcription factors relevant to metabolic regulation. Provide a detailed rationale for the selection of TFTEA and explain how it contributes to understanding metabolic regulation.\"\n  },\n  \"Part 5\": {\n    \"Title\": \"Differential Signaling Analysis\",\n    \"Referability\": \"High\",\n    \"Reason\": \"Differential signaling analysis is highly relevant as it can help identify key pathways and circuits that differ between highly differentiated and dedifferentiated liposarcoma.\",\n    \"Suggestions\": \"We should adapt the differential signaling analysis to focus on metabolic pathways. This involves using the limma package for differential expression analysis and performing functional annotation specific to metabolic processes. Ensure that the analysis is well-documented and justifies the selection of metabolic pathways. Provide a detailed explanation of the limma package and its relevance to our study.\"\n  },\n  \"Part 6\": {\n    \"Title\": \"Association with Hallmarks of Cancer\",\n    \"Referability\": \"Medium\",\n    \"Reason\": \"Associating differentially activated circuits with cancer hallmarks can provide a broader understanding of the biological significance of our findings. This can be useful for contextualizing metabolic differences within the framework of cancer biology.\",\n    \"Suggestions\": \"We should use the CHAT tool to annotate our findings with cancer hallmarks, emphasizing those related to metabolism. This will help in understanding how metabolic characteristics contribute to cancer progression and differentiation in liposarcoma. Ensure that the focus remains on hallmarks relevant to metabolic processes. Provide a detailed explanation of the CHAT tool and its relevance to our study.\"\n  }\n}\n```"
                }
            ]
        }
    ],
    "input_tokens_num": 120046,
    "output_tokens_num": 5059
}